

Masako Harada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7598238/publications.pdf>

Version: 2024-02-01

17
papers

779
citations

840776

11
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

1558
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-125b Down-regulates Matrix Metalloproteinase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion. <i>Journal of Biological Chemistry</i> , 2012, 287, 29899-29908.	3.4	161
2	DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. <i>Experimental Cell Research</i> , 2009, 315, 2941-2952.	2.6	153
3	A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. <i>Cancers</i> , 2020, 12, 1852.	3.7	148
4	MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma. <i>Oncogenesis</i> , 2012, 1, e3-e3.	4.9	87
5	Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2041-2050.	1.3	42
6	MicroRNA-203 Inversely Correlates with Differentiation Grade, Targets c-MYC, and Functions as a Tumor Suppressor in cSCC. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2485-2494.	0.7	39
7	Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. <i>Blood Cancer Journal</i> , 2011, 1, e31-e31.	6.2	33
8	The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. <i>Oncotarget</i> , 2015, 6, 37930-37947.	1.8	32
9	MiR-200c Regulates Noxa Expression and Sensitivity to Proteasomal Inhibitors. <i>PLoS ONE</i> , 2012, 7, e36490.	2.5	25
10	Nano-immunoimaging. <i>Nanoscale Horizons</i> , 2020, 5, 628-653.	8.0	22
11	Engineering Extracellular Vesicles to Target Pancreatic Tissue <i>In Vivo</i> . <i>Nanotheranostics</i> , 2021, 5, 378-390.	5.2	19
12	Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display. <i>Bioengineering</i> , 2022, 9, 56.	3.5	12
13	Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 2254-2254.	1.4	4
14	The mTOR Kinase Inhibitor AZD-2014 Effectively Reverses XPO1/CRM1 Antagonist KPT-185-induced Glycolysis / Gluconeogenesis, Enhancing Antitumor Effects in Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 925-925.	1.4	1
15	Abstract 1098: MiR-203 suppresses cutaneous squamous cell carcinoma growth and targets the myc oncogene. , 2016, , .		1
16	Metabolic Re-Programming in Notch-Activated T-ALL By mTOR Inhibitor AZD2014 Combined with L-Asparaginase. <i>Blood</i> , 2014, 124, 3626-3626.	1.4	0
17	Bone Marrow Adipocyte-Derived Free Fatty Acids Induce Gene Signature Linking Transcription with Metabolic Changes That Contribute to Survival of Acute Monocytic Leukemia Cells. <i>Blood</i> , 2014, 124, 1013-1013.	1.4	0